This double-blind, placebo-controlled trial will evaluate the safety and immunogenicity of a seven valent pneumococcal conjugate vaccine in 60 presumed HIV-infected infants between 56 and 180 days of age. Data of study is currently being analyzed and patients continue to be followed.
Showing the most recent 10 out of 459 publications